Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rhys Jones

Showing results (201-210 of 203) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 203 results.
Journal of Medicinal Chemistry|December 9, 2024
Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of CancerRebecca A Gallego, Sujin Cho-Schultz, Matthew Del Bel, et al.
Nature|April 30, 2025
Global evolution of inflammatory bowel disease across epidemiologic stagesLindsay Hracs, Joseph W Windsor, Julia Gorospe, et al.
Cell Chemical Biology|August 9, 2023
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancerShikhar Sharma, Chi-Yeh Chung, Sean Uryu, et al.
Pageof 21

Showing results (201-210 of 203) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 203 results.
Journal of Medicinal Chemistry|December 9, 2024
Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of CancerRebecca A Gallego, Sujin Cho-Schultz, Matthew Del Bel, et al.
Nature|April 30, 2025
Global evolution of inflammatory bowel disease across epidemiologic stagesLindsay Hracs, Joseph W Windsor, Julia Gorospe, et al.
Cell Chemical Biology|August 9, 2023
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancerShikhar Sharma, Chi-Yeh Chung, Sean Uryu, et al.
Pageof 21